• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Biodel

edit

Biodel Inc. (Biodel) is a development-stage company. The Company is a biopharmaceutical company focused on the development and commercialization of treatments for diabetes. It develops its product candidates by applying its formulation technologies to existing drugs. Its product candidate is Linjeta. It has formulated Linjeta as rapid-acting mealtime insulin for the treatment of patients with Type I and Type II diabetes. Earlier stage product candidates include follow-on and second generation rapid-acting mealtime insulins or insulin analogs, VIAtab, a sublingual tablet formulation of insulin, a line of basal insulins, and a formulation of glucagon.

Recent Milestones

edit

• 
  Biodel received $30M in Venture Round funding. (5/13/11)
  Posted 5/13/11 at 6:19pm via masshightech.com
• 
  Biodel added Errol B. De Souza as President & CEO.
  Posted 5/13/11 at 6:19pm
• 
  Went public with stock symbol NASDAQ:BIOD.
  Posted 5/13/11 at 6:20pm
• 
  Biodel added Gerard J. Michel as CFO.
  Posted 5/13/11 at 6:19pm

Videos

Screenshots

edit

Stock Price

Sources

1. Connecticut’s Biodel plans to raise $30M (masshightech.com) [edit]